History of how viruses can fight cancer: From the miraculous healings to the approval of oncolytic viruses

Since the nineteenth century, several reports in the historical medical literature emphasized that, occasionally, cancer patients showed a clinical remission, called “Saint Peregrine tumor” as a result of natural infections. Moreover, additional evidence indicated that viruses show a tropism toward...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biochimie 2023-03, Vol.206, p.89-92
Hauptverfasser: Bifulco, Maurizio, Di Zazzo, Erika, Napolitano, Fabiana, Malfitano, Anna Maria, Portella, Giuseppe
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 92
container_issue
container_start_page 89
container_title Biochimie
container_volume 206
creator Bifulco, Maurizio
Di Zazzo, Erika
Napolitano, Fabiana
Malfitano, Anna Maria
Portella, Giuseppe
description Since the nineteenth century, several reports in the historical medical literature emphasized that, occasionally, cancer patients showed a clinical remission, called “Saint Peregrine tumor” as a result of natural infections. Moreover, additional evidence indicated that viruses show a tropism toward cancer cells, leading to the discovery of oncolytic activity of several viruses, called oncolytic viruses (OVs). With the technological and scientific advancements, the advent of rodent models, the establishment of in vitro cell lines, the introduction of methods for virus propagation, several attempts through the 1950s and 1970s have been made to increase OVs specificity, efficacy and safety; however, inconclusive/negative results have been reached and many researchers abandoned the field. Only in the later 1990s, the genetic engineering and the recombinant DNA techniques that allowed the generation of potent, specific and safe OVs and a better understanding of cancer cells renewed the interest in virotherapy. Currently, virotherapy represents a cancer therapeutic strategy based on the use of OVs that selectively infect and lyse cancer cells, without harming normal cells. Over the past years, several “natural” and “genetic engineered” viruses, have been investigated in clinical studies and some of them revealed encouraging results. Recently, the clinical use of OVs has also been supported by the immune stimulatory property of OVs against tumor cells. Here, we analyze the early oncolytic virotherapy before genetic engineering to highlight the relevant progresses reached, and the mechanism to stimulate host immune response, a significant challenge in current virotherapy field. •Occurrence of cancer remission concomitantly with naturally viral infections.•Modern molecular biology techniques allowed generation of new oncolytic viruses.•Clinical trials guided the approval of oncolytic viruses for cancer treatment.•Beyond cancer cell lysis, oncolytic viruses display immune-stimulatory properties.
doi_str_mv 10.1016/j.biochi.2022.10.008
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2728144804</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0300908422002759</els_id><sourcerecordid>2728144804</sourcerecordid><originalsourceid>FETCH-LOGICAL-c292t-2668b4e32df1ca5de97d88ecd4d6f71852be8a0b03f00d5efb4d3772ab8ee6673</originalsourceid><addsrcrecordid>eNp9kMFO3DAQhi1EBVvKGyDkI5dsx3bieDkgoVUplZB6ac-WY0-IV8l6sZNF-_Y4XeiR04xm_vln5iPkisGSAZPfN8vGB9v5JQfOc2kJoE7IgkmhCsmUOCULEADFClR5Tr6mtAGACvjqjJwLyWtRy2pBNo8-jSEeaGhpF17p3scpYaLWbGnrn7txzizGW_oQw0DHDungo7FTH6ZEOzS93z4nOoZ_LbPbxbA3_ewWtjb0h9HbD89v5Etr-oSX7_GC_H348Wf9WDz9_vlrff9UWL7iY8GlVE2JgruWWVM5XNVOKbSudLKtmap4g8pAA6IFcBW2TelEXXPTKEQpa3FBbo6--ZaXCdOoB58s9r3ZYj5a85orVpYKyiwtj1IbQ0oRW72LfjDxoBnombLe6CNlPVOeq5lyHrt-3zA1A7r_Qx9Ys-DuKMD8595j1Ml6zBydj2hH7YL_fMMbW3CRmQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2728144804</pqid></control><display><type>article</type><title>History of how viruses can fight cancer: From the miraculous healings to the approval of oncolytic viruses</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Bifulco, Maurizio ; Di Zazzo, Erika ; Napolitano, Fabiana ; Malfitano, Anna Maria ; Portella, Giuseppe</creator><creatorcontrib>Bifulco, Maurizio ; Di Zazzo, Erika ; Napolitano, Fabiana ; Malfitano, Anna Maria ; Portella, Giuseppe</creatorcontrib><description>Since the nineteenth century, several reports in the historical medical literature emphasized that, occasionally, cancer patients showed a clinical remission, called “Saint Peregrine tumor” as a result of natural infections. Moreover, additional evidence indicated that viruses show a tropism toward cancer cells, leading to the discovery of oncolytic activity of several viruses, called oncolytic viruses (OVs). With the technological and scientific advancements, the advent of rodent models, the establishment of in vitro cell lines, the introduction of methods for virus propagation, several attempts through the 1950s and 1970s have been made to increase OVs specificity, efficacy and safety; however, inconclusive/negative results have been reached and many researchers abandoned the field. Only in the later 1990s, the genetic engineering and the recombinant DNA techniques that allowed the generation of potent, specific and safe OVs and a better understanding of cancer cells renewed the interest in virotherapy. Currently, virotherapy represents a cancer therapeutic strategy based on the use of OVs that selectively infect and lyse cancer cells, without harming normal cells. Over the past years, several “natural” and “genetic engineered” viruses, have been investigated in clinical studies and some of them revealed encouraging results. Recently, the clinical use of OVs has also been supported by the immune stimulatory property of OVs against tumor cells. Here, we analyze the early oncolytic virotherapy before genetic engineering to highlight the relevant progresses reached, and the mechanism to stimulate host immune response, a significant challenge in current virotherapy field. •Occurrence of cancer remission concomitantly with naturally viral infections.•Modern molecular biology techniques allowed generation of new oncolytic viruses.•Clinical trials guided the approval of oncolytic viruses for cancer treatment.•Beyond cancer cell lysis, oncolytic viruses display immune-stimulatory properties.</description><identifier>ISSN: 0300-9084</identifier><identifier>EISSN: 1638-6183</identifier><identifier>DOI: 10.1016/j.biochi.2022.10.008</identifier><identifier>PMID: 36273765</identifier><language>eng</language><publisher>France: Elsevier B.V</publisher><subject>Cancer ; Genetic Engineering ; Humans ; Immuno-stimulation ; Infection ; Neoplasms - pathology ; Oncolytic Virotherapy - methods ; Oncolytic viruses ; Oncolytic Viruses - genetics</subject><ispartof>Biochimie, 2023-03, Vol.206, p.89-92</ispartof><rights>2022</rights><rights>Copyright © 2022. Published by Elsevier B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c292t-2668b4e32df1ca5de97d88ecd4d6f71852be8a0b03f00d5efb4d3772ab8ee6673</citedby><cites>FETCH-LOGICAL-c292t-2668b4e32df1ca5de97d88ecd4d6f71852be8a0b03f00d5efb4d3772ab8ee6673</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0300908422002759$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36273765$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bifulco, Maurizio</creatorcontrib><creatorcontrib>Di Zazzo, Erika</creatorcontrib><creatorcontrib>Napolitano, Fabiana</creatorcontrib><creatorcontrib>Malfitano, Anna Maria</creatorcontrib><creatorcontrib>Portella, Giuseppe</creatorcontrib><title>History of how viruses can fight cancer: From the miraculous healings to the approval of oncolytic viruses</title><title>Biochimie</title><addtitle>Biochimie</addtitle><description>Since the nineteenth century, several reports in the historical medical literature emphasized that, occasionally, cancer patients showed a clinical remission, called “Saint Peregrine tumor” as a result of natural infections. Moreover, additional evidence indicated that viruses show a tropism toward cancer cells, leading to the discovery of oncolytic activity of several viruses, called oncolytic viruses (OVs). With the technological and scientific advancements, the advent of rodent models, the establishment of in vitro cell lines, the introduction of methods for virus propagation, several attempts through the 1950s and 1970s have been made to increase OVs specificity, efficacy and safety; however, inconclusive/negative results have been reached and many researchers abandoned the field. Only in the later 1990s, the genetic engineering and the recombinant DNA techniques that allowed the generation of potent, specific and safe OVs and a better understanding of cancer cells renewed the interest in virotherapy. Currently, virotherapy represents a cancer therapeutic strategy based on the use of OVs that selectively infect and lyse cancer cells, without harming normal cells. Over the past years, several “natural” and “genetic engineered” viruses, have been investigated in clinical studies and some of them revealed encouraging results. Recently, the clinical use of OVs has also been supported by the immune stimulatory property of OVs against tumor cells. Here, we analyze the early oncolytic virotherapy before genetic engineering to highlight the relevant progresses reached, and the mechanism to stimulate host immune response, a significant challenge in current virotherapy field. •Occurrence of cancer remission concomitantly with naturally viral infections.•Modern molecular biology techniques allowed generation of new oncolytic viruses.•Clinical trials guided the approval of oncolytic viruses for cancer treatment.•Beyond cancer cell lysis, oncolytic viruses display immune-stimulatory properties.</description><subject>Cancer</subject><subject>Genetic Engineering</subject><subject>Humans</subject><subject>Immuno-stimulation</subject><subject>Infection</subject><subject>Neoplasms - pathology</subject><subject>Oncolytic Virotherapy - methods</subject><subject>Oncolytic viruses</subject><subject>Oncolytic Viruses - genetics</subject><issn>0300-9084</issn><issn>1638-6183</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMFO3DAQhi1EBVvKGyDkI5dsx3bieDkgoVUplZB6ac-WY0-IV8l6sZNF-_Y4XeiR04xm_vln5iPkisGSAZPfN8vGB9v5JQfOc2kJoE7IgkmhCsmUOCULEADFClR5Tr6mtAGACvjqjJwLyWtRy2pBNo8-jSEeaGhpF17p3scpYaLWbGnrn7txzizGW_oQw0DHDungo7FTH6ZEOzS93z4nOoZ_LbPbxbA3_ewWtjb0h9HbD89v5Etr-oSX7_GC_H348Wf9WDz9_vlrff9UWL7iY8GlVE2JgruWWVM5XNVOKbSudLKtmap4g8pAA6IFcBW2TelEXXPTKEQpa3FBbo6--ZaXCdOoB58s9r3ZYj5a85orVpYKyiwtj1IbQ0oRW72LfjDxoBnombLe6CNlPVOeq5lyHrt-3zA1A7r_Qx9Ys-DuKMD8595j1Ml6zBydj2hH7YL_fMMbW3CRmQ</recordid><startdate>202303</startdate><enddate>202303</enddate><creator>Bifulco, Maurizio</creator><creator>Di Zazzo, Erika</creator><creator>Napolitano, Fabiana</creator><creator>Malfitano, Anna Maria</creator><creator>Portella, Giuseppe</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202303</creationdate><title>History of how viruses can fight cancer: From the miraculous healings to the approval of oncolytic viruses</title><author>Bifulco, Maurizio ; Di Zazzo, Erika ; Napolitano, Fabiana ; Malfitano, Anna Maria ; Portella, Giuseppe</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c292t-2668b4e32df1ca5de97d88ecd4d6f71852be8a0b03f00d5efb4d3772ab8ee6673</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Cancer</topic><topic>Genetic Engineering</topic><topic>Humans</topic><topic>Immuno-stimulation</topic><topic>Infection</topic><topic>Neoplasms - pathology</topic><topic>Oncolytic Virotherapy - methods</topic><topic>Oncolytic viruses</topic><topic>Oncolytic Viruses - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bifulco, Maurizio</creatorcontrib><creatorcontrib>Di Zazzo, Erika</creatorcontrib><creatorcontrib>Napolitano, Fabiana</creatorcontrib><creatorcontrib>Malfitano, Anna Maria</creatorcontrib><creatorcontrib>Portella, Giuseppe</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biochimie</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bifulco, Maurizio</au><au>Di Zazzo, Erika</au><au>Napolitano, Fabiana</au><au>Malfitano, Anna Maria</au><au>Portella, Giuseppe</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>History of how viruses can fight cancer: From the miraculous healings to the approval of oncolytic viruses</atitle><jtitle>Biochimie</jtitle><addtitle>Biochimie</addtitle><date>2023-03</date><risdate>2023</risdate><volume>206</volume><spage>89</spage><epage>92</epage><pages>89-92</pages><issn>0300-9084</issn><eissn>1638-6183</eissn><abstract>Since the nineteenth century, several reports in the historical medical literature emphasized that, occasionally, cancer patients showed a clinical remission, called “Saint Peregrine tumor” as a result of natural infections. Moreover, additional evidence indicated that viruses show a tropism toward cancer cells, leading to the discovery of oncolytic activity of several viruses, called oncolytic viruses (OVs). With the technological and scientific advancements, the advent of rodent models, the establishment of in vitro cell lines, the introduction of methods for virus propagation, several attempts through the 1950s and 1970s have been made to increase OVs specificity, efficacy and safety; however, inconclusive/negative results have been reached and many researchers abandoned the field. Only in the later 1990s, the genetic engineering and the recombinant DNA techniques that allowed the generation of potent, specific and safe OVs and a better understanding of cancer cells renewed the interest in virotherapy. Currently, virotherapy represents a cancer therapeutic strategy based on the use of OVs that selectively infect and lyse cancer cells, without harming normal cells. Over the past years, several “natural” and “genetic engineered” viruses, have been investigated in clinical studies and some of them revealed encouraging results. Recently, the clinical use of OVs has also been supported by the immune stimulatory property of OVs against tumor cells. Here, we analyze the early oncolytic virotherapy before genetic engineering to highlight the relevant progresses reached, and the mechanism to stimulate host immune response, a significant challenge in current virotherapy field. •Occurrence of cancer remission concomitantly with naturally viral infections.•Modern molecular biology techniques allowed generation of new oncolytic viruses.•Clinical trials guided the approval of oncolytic viruses for cancer treatment.•Beyond cancer cell lysis, oncolytic viruses display immune-stimulatory properties.</abstract><cop>France</cop><pub>Elsevier B.V</pub><pmid>36273765</pmid><doi>10.1016/j.biochi.2022.10.008</doi><tpages>4</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0300-9084
ispartof Biochimie, 2023-03, Vol.206, p.89-92
issn 0300-9084
1638-6183
language eng
recordid cdi_proquest_miscellaneous_2728144804
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects Cancer
Genetic Engineering
Humans
Immuno-stimulation
Infection
Neoplasms - pathology
Oncolytic Virotherapy - methods
Oncolytic viruses
Oncolytic Viruses - genetics
title History of how viruses can fight cancer: From the miraculous healings to the approval of oncolytic viruses
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T17%3A56%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=History%20of%20how%20viruses%20can%20fight%20cancer:%20From%20the%20miraculous%20healings%20to%20the%20approval%20of%20oncolytic%20viruses&rft.jtitle=Biochimie&rft.au=Bifulco,%20Maurizio&rft.date=2023-03&rft.volume=206&rft.spage=89&rft.epage=92&rft.pages=89-92&rft.issn=0300-9084&rft.eissn=1638-6183&rft_id=info:doi/10.1016/j.biochi.2022.10.008&rft_dat=%3Cproquest_cross%3E2728144804%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2728144804&rft_id=info:pmid/36273765&rft_els_id=S0300908422002759&rfr_iscdi=true